News
ALDX
3.080
+5.48%
0.160
Weekly Report: what happened at ALDX last week (0318-0322)?
Weekly Report · 3d ago
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered royalties for ex-US. Aldeyra Therapeutics has $142M in cash and is expected to burn $40M in 2024. The company signed an option agreement to license its lead drug for dry eye disease.
Seeking Alpha · 4d ago
Weekly Report: what happened at ALDX last week (0311-0315)?
Weekly Report · 03/18 09:46
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/13 06:20
Weekly Report: what happened at ALDX last week (0304-0308)?
Weekly Report · 03/11 09:45
Strong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic Partnerships
Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Aldeyra Therapeutics (ALDX – Research Report). The associated price target is $11.00. The potential resolution of the Reproxalap CRL with the FDA provides a clear path forward for the company.
TipRanks · 03/10 21:27
Aldeyra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Aldeyra Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 8 cents per share. The mean expectation of eight analysts was for a loss of 14 cents. The average analyst rating on the company's shares is "buy"
Reuters · 03/08 04:30
Aldeyra Therapeu: Annual report
Press release · 03/07 22:55
Aldeyra Therapeutics files for $200M mixed securities shelf
Aldeyra Therapeutics files for $200M mixed securities shelf. The company has filed a prospectus related to the offer and sell of up to $200 million mixed securities. Aldeyra is a biopharmaceutical company with a focus on cancer treatment.
Seeking Alpha · 03/07 22:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
NKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. VTv Therapeutics stock moved upwards by 13.17%. Cerus ( NASDAQ:CERS) increased by 9.09% during the day. The company's, Q4 earnings came out today.
Benzinga · 03/05 21:31
Weekly Report: what happened at ALDX last week (0226-0301)?
Weekly Report · 03/04 09:46
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
NASDAQ · 03/01 14:45
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
NASDAQ · 02/28 12:34
Weekly Report: what happened at ALDX last week (0219-0223)?
Weekly Report · 02/26 09:50
Weekly Report: what happened at ALDX last week (0212-0216)?
Weekly Report · 02/19 09:50
Aldeyra CEO Speaks at Oppenheimer Healthcare Conference
TipRanks · 02/13 21:13
Weekly Report: what happened at ALDX last week (0205-0209)?
Weekly Report · 02/12 09:46
Weekly Report: what happened at ALDX last week (0129-0202)?
Weekly Report · 02/05 09:50
Aldeyra Therapeu: Statement of acquisition of beneficial ownership by individuals
Press release · 01/30 00:35
Weekly Report: what happened at ALDX last week (0122-0126)?
Weekly Report · 01/29 09:46
More
Webull provides a variety of real-time ALDX stock news. You can receive the latest news about Aldeyra Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.